mCerulean-hCOL1A1
(Plasmid #140112)

• Purpose: Expresses fluorescently-tagged human Type I procollagen α1 chain with mCerulean replacing exon 2-3 retaining N-propeptide minor triple helix and N-terminal cleavage site
• Depositing Lab: Sergey Leikin
• Publication: Fluorescent protein-tagged human type I procollagen expression vectors (unpublished)

Backbone

• Vector backbone: pcDNA3.1
• Total vector size (bp): 10704
• Vector type: Mammalian Expression
• Selectable markers: Neomycin (select with G418)

Growth in Bacteria

• Bacterial Resistance(s): Ampicillin, 100 μg/mL
• Growth Temperature: 37°C
• Growth Strain(s): DH5alpha
• Copy number: Unknown

Gene/Insert

• Gene/Insert name: Type I procollagen α1
• Species: H. sapiens (human)
• Insert Size (bp): 5232
• Mutation: COL1A1 exons 2-3 replaced by fluorescent tag
• GenBank ID: NM_000088
• Entrez Gene: COL1A1 (a.k.a. CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3, OI4)
• Promoter: CMV
• Tag / Fusion Protein:
  • mCerulean (N terminal on insert)

Cloning Information

• Cloning method: Restriction Enzyme
• 5′ cloning site: NotI, XbaI (unknown if destroyed)
• 3′ cloning site: None (destroyed during cloning)
• 5′ sequencing primer: CGC AAA TGG GCG GTA GGC GTG
• 3′ sequencing primer: TAG AAG GCA CAG TCG AGG

Resource Information

• Supplemental Documents:
  • mCerulean-hCOL1A1.gbk
• A portion of this plasmid was derived from a plasmid made by: Origene

Terms and Licenses

• Academic/Nonprofit Terms:
  • UBMTA
• Industry Terms:
  • Not Available to Industry

Depositor Comments

These human type I procollagen plasmids were designed and validated for human osteoblasts and fibroblasts similar to their previously published/shared murine counterparts e.g. eGFP-Proα1 (Plasmid #119843) https://www.addgene.org/Sergey_Leikin/. Their expression in other cells might disrupt assembly, folding and trafficking of type I procollagen, resulting in artifacts. Even in human osteoblasts and fibroblasts, overexpression of exogenous proα2 might cause intracellular trafficking and degradation of some transfected chains as monomers without integration into normal heterotrimeric (proα1)2proα2 procollagen molecules,. Overexpression of exogenous proα1 might result in excessive formation of homotrimeric (proα1)3 molecules, some of which might contain fluorescent tags on two or even all three proα1 chains, potentially causing severe disruptions in cellular function.

In our experience with the murine plasmids expressed in primary osteoblasts or the MC3T3 osteoblastic cell line, the best evidence of normal behavior of the transfected chains is the appearance of fluorescent extracellular collagen fibers ~ 12-24 h after transfection. These were harder to observe in human Saos2 osteoblast cell line transfected with the human type I procollagen plasmids (likely due to slower fibrillogenesis and more complete cleavage of the fluorescently-tagged N-propeptide prior to collagen fibril formation).

We strongly recommend following these guidelines when using the plasmids

1) Only human cells that have high expression of endogenous type I procollagen and that express fewer transfected than endogenous chains are suitable for studies of physiologically-relevant processes with these constructs.
2) At least 100 μM ascorbic acid at and after transfection is required to ensure proper procollagen folding (for some cells, preincubation with ascorbic acid before transfection might be needed).
3) Stable transfection causes excessive accumulation of tagged chains in the ER over time, disruption of ER homeostasis, and disruptions and changes in cellular function. Therefore, low to moderate transient transfection is recommended for studies of physiologically relevant processes. Optimization of transfection efficiency is needed for all cell types.
4) Experiments beyond 24h after transfection are not recommended, to avoid the excessive accumulation of tagged chains in the ER and cell malfunction caused by increased procollagen synthesis.
5) Excessive expression of transfected chains might cause rapid accumulation of large procollagen aggregates in the ER, resulting in cellular malfunction and death.

Contact information: Shakib Omari () Sergey Leikin ()